New research suggests that people who come off popular slimming jabs like semaglutide or tirzepatide may regain lost weight much more quickly than those who stop traditional lifestyle programs.
Published data in a prominent health publication shows that while overweight individuals can lose about a fifth of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.
"Individuals buying such drugs should be informed of the risk of quick rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of recovery implies a return to starting mass within about a year and a half.
Analyzing Treatments
The research, which looked at dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills.
Scientists emphasize that people who lose weight through diet and exercise typically experience a slower creep back—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Doctors believe the mechanism of the jabs accounts for the amplified regain.
The injections copy a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its own natural hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
Health authorities advise the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals contend that, considering the likelihood of relapse, the treatment should be considered long-term.
This view is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
Individuals who have come off the jabs describe a sudden resurgence of cravings.
"It felt as if something that goes on and I was suddenly ravenous," said an individual.
The struggle is exacerbated if patients have not adopted permanent lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is greater among women than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and long-term success hinges on integrated behavioural management.
